Innovation-Driven Growth:
FDA clearance of the eVO2peak module in December 2025 and multiple FDA‑cleared algorithms, alongside the physIQ acquisition adding mature analytics and biosensor pipelines, point to expanding technical capabilities. Active clinical programs (e.g., the OCORO all‑remote study) and conference presence indicate continued product and evidence development.
Market Expansion:
Operations span 26+ countries with stated plans to extend access to Europe and Asia by 2026, signaling geographic scaling. Regulatory momentum and multi‑million hours of on‑body data suggest readiness to support broader deployment across markets.
Strong Hiring & Retention:
A reported 51–200 employee range, 32 new hires in 2025, and ongoing postings (e.g., Director of Regulatory Affairs) reflect organizational scaling. Quality certifications (ISO 13485/MDSAP) and a dedicated production operations suite underscore maturing infrastructure alongside headcount growth.
